Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yonggang Liu
Observed name:
yonggang liu
Institution:
Beijing University of Chinese Medicine
Observed institutions:
Beijing University of Chinese Medicine,
The First People's Hospital of Shunde,
Nanfang Hospital,
Tianjin Medical University,
Southern Medical University
ORCID:
0000-0002-8486-6332
Observed ORCID:
0000-0002-8486-6332
OpenAlex ID:
A5090889549
Inhibition of KIF20A enhances the immunotherapeutic effect of hepatocellular carcinoma by enhancing c-Myc ubiquitination
2024
·
Shujia Chen
, Lili Zhao
, et al.
·
Cancer Letters
·
41
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study
2025
·
Rui Su
, Xuemei Tao
, et al.
·
Hepatology
·
20
Interferon-induced transmembrane protein 2 promotes epithelial-mesenchymal transition by activating transforming growth factor-β1/small mother against decapentaplegic 2 signaling in gastric cancer
2021
·
Yonggang Liu
, Minyu Zhou
, et al.
·
Molecular Biology Reports
·
12
Unveiling the immunoregulatory role of interferon-induced transmembrane protein 2 through the JAK/STAT3/PDL1 pathway in gastric cancer
2024
·
Yonggang Liu
, Jiyun Liang
, et al.
·
International Immunopharmacology
·
6
Injectable multi-component hydrogel as an inhibitor of choline kinase α achieved the treatment of malignant ascites by inhibiting PI3K/AKT/mTOR signaling pathway
2026
·
Yuqin Yang
, Jinchai Qi
, et al.
·
Journal of Advanced Research
·
3
Predicting Immunotherapy Outcomes in NSCLC Using RNA and Pathology from Multicenter Clinical Trials
2025
·
Zhaojun Wang
, Yiran Fang
, et al.
·
Advanced Science
·
1
HAUS5 is a novel prognostic biomarker for hepatocellular carcinoma that is associated with poor clinical outcomes
2023
·
yonggang liu
, Jiyun Liang
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
7
Citation count:
83
H-index:
4
I10-index:
3
Year
Topic
Type